Document is current
Any future updates will be listed below
-
Authors
Hauber, Brett
Hong, Agnes
Hunsche, Elke
Maculaitis, Martine C.
Collins, Sean P.
-
Funding
Funding for this research was provided by:
Pfizer
Sumitomo Pharma Switzerland GmbH
- License Information
-
More Information
Article History
Received: 22 March 2024
Accepted: 24 July 2024
First Online: 21 August 2024
Declarations
:
: Brett Hauber and Agnes Hong are employees of Pfizer Inc., with stock ownership in Pfizer Inc. Elke Hunsche is an employee of Sumitomo Pharma Switzerland GmbH (formerly Myovant Sciences GmbH). Martine C. Maculaitis is an employee of Oracle Life Sciences, which received funding from Pfizer Inc. to conduct and report on the study. Sean P. Collins is currently Vice Chair of Faculty Affairs in the Department of Radiation Oncology at the University of South Florida; he is a consultant for Boston Scientific Corporation, Sumitomo Pharma America, Inc. (formerly Myovant Sciences Inc.), and Pfizer Inc.; and has received honoraria and research funding from Accuray Inc.
: Participants were required to provide electronic informed consent. The final protocol and informed consent documentation were reviewed by Sterling International Review Board (Atlanta, GA); an exemption determination was granted on October 28, 2021 (Protocol ID # 9398-MMaculaitis). The study complied with all legal and regulatory requirements, as well as with scientific purpose, value, and rigor, and followed generally accepted research practices described in Good Practices for Outcomes Research issued by the International Society for Pharmacoeconomics and Outcomes Research.
